MetaCap

Aprea Therapeutics (APRE) vs Jaguar Health (JAGX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aprea Therapeutics is the larger company by market cap ($3.2 million vs $3.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

APRE-62.15%JAGX-95.46%
+7%-47%-100%
Oct 7, 20261 yearNov 20, 2026
APRE-62.11%JAGX-95.26%
+5%-48%-100%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

APRE versus JAGX key metrics
MetricAPREJAGX
Share price$0.229$0.227
Market cap$3.25M$3.03M
1-day change-53.56%-30.58%
EPS (TTM)$-0.57$-257.15
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$11.51M
Revenue growth (YoY)—-1.52%
Net income (latest FY)$-12.60M$-53.58M
Gross margin—67.21%
Operating margin—-398.82%
Net margin—-465.42%
52-week high$1.49$981.75
52-week low$0.2036$0.22
Distance from 52-week high-84.63%-99.98%
Analyst consensusnone—
Avg. price target upside+1528.82%—
Average volume388.67K2.40M
Shares outstanding14.19M13.35M
Employees847
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aprea Therapeutics

APRE stock →

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

About Jaguar Health

JAGX stock →

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health.

Health Care · Biotechnology: Pharmaceutical Preparations · 47 employees

APRE vs JAGX FAQ

Which is bigger, Aprea Therapeutics or Jaguar Health?

Aprea Therapeutics (APRE) is larger, with a market capitalization of $3.25M compared with $3.03M for Jaguar Health (JAGX).

Are Aprea Therapeutics and Jaguar Health in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons